Association between age at diagnosis and the presence of EGFR mutations in female patients with resected non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 5, Issue 12, 2010, Pages 1949-1952

  Choi, Yoon Hee ^a   Lee, Jin Kyung ^a   Kang, Hye Jin ^a   Lee, Tae Sup ^a   Kim, Hye Ryoun ^a   Kim, Cheol Hyeon ^a   Koh, Jae Soo ^a   Baek, Hee Jong ^a   Lee, Jae Cheol ^a   Na, Im Il ^a  

^a Korea Cancer Center Hospital   (South Korea)

Author keywords

Age; EGFR mutations; Female; Non small cell lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB;

ADENOID CYSTIC CARCINOMA; ADENOSQUAMOUS CARCINOMA; ADULT; AGE; AGED; ARTICLE; CANCER CENTER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURGERY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KOREA; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SMOKING; SURGICAL TECHNIQUE; TREATMENT RESPONSE;

EID: 78650477805     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181f38816     Document Type: Article

References (36)

1. Fu JB, Kau TY, Severson RK, et al. Lung cancer in women: analysis of the national Surveillance, Epidemiology, and End Results database. Chest 2005;127:768-777.
2. Won Y, Sung J, Jung K, et al. Nationwide cancer incidence in Korea, 2003-2005. Cancer Res Treat 2009;41:122-131.
3. Hotta K, Kiura K, Takigawa N, et al. Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung: Okayama Lung Cancer Study Group experience. J Cancer Res Clin Oncol 2009;135:117-123.
4. Minami H, Yoshimura M, Miyamoto Y, et al. Lung cancer in women: sex-associated differences in survival of patients undergoing resection for lung cancer. Chest 2000;118:1603-1609. (Pubitemid 32001783)
5. Matsuo K, Ito H, Yatabe Y, et al. Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese. Cancer Sci 2007;98:96-101. (Pubitemid 44803926)
6. Na II, Choe du H, Kim CH, et al. Age at diagnosis predicts outcomes in gefitinib-treated female patients with non-small-cell lung cancer. Lung Cancer 2010;68:295-298.
7. Planchard D, Loriot Y, Goubar A, et al. Differential expression of biomarkers in men and women. Semin Oncol 2009;36:553-565.
8. Chen K, Chang C, Yu C, et al. Distribution according to histologic type and outcome by gender and age group in Taiwanese patients with lung carcinoma. Cancer 2005;103:2566-2574. (Pubitemid 40800536)
9. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall- cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139. (Pubitemid 38637993)
10. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304: 1497-1500. (Pubitemid 38720929)
11. Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005;23:8081-8092. (Pubitemid 46657411)
12. Visbal AL, Williams BA, Nichols FC, et al. Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg 2004;78:209 -215; discussion 215.
13. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353: 123-132. (Pubitemid 41058344)
14. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366: 1527-1537. (Pubitemid 41540110)
15. Chang A, Parikh P, Thongprasert S, et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol 2006;1:847-855. (Pubitemid 47181391)
16. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-346. (Pubitemid 40425952)
17. Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919-8923. (Pubitemid 39665498)
18. Yang C, Yu C, Shih J, et al. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-smallcell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 2008;26:2745-2753.
19. Mok TS, Wu Y, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
20. Douillard JY, Shepherd FA, Hirsh V, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-smallcell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010;28:744-752.
21. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-1717. (Pubitemid 27260107)
22. Na II, Kang HJ, Cho SY, et al. EGFR mutations and human papillomavirus in squamous cell carcinoma of tongue and tonsil. Eur J Cancer 2007;43:520-526. (Pubitemid 46177596)
23. Newton CR, Graham A, Heptinstall LE, et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res 1989;17:2503-2516. (Pubitemid 19103235)
24. Thelwell N, Millington S, Solinas A, et al. Mode of action and application of Scorpion primers to mutation detection. Nucleic Acids Res 2000;28:3752-3761.
25. Bell DW, Brannigan BW, Matsuo K, et al. Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms. Clin Cancer Res 2008;14: 4079-4084.
26. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer- molecular and clinical predictors of outcome. N Engl J Med 2005;353: 133-144. (Pubitemid 41058345)
27. Sugio K, Uramoto H, Ono K, et al. Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. Br J Cancer 2006;94: 896-903.
28. Kim YT, Kim TY, Lee DS, et al. Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung. Lung Cancer 2008;59:111-118.
29. Nose N, Sugio K, Oyama T, et al. Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. J Clin Oncol 2009;27:411-417.
30. Raso MG, Behrens C, Herynk MH, et al. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res 2009; 15:5359-5368.
31. Dacic S. EGFR assays in lung cancer. Adv Anat Pathol 2008;15:241-247.
32. Marchetti A, Felicioni L, Buttitta F. Assessing EGFR mutations. N Engl J Med 2006;354:526 -528, author reply 526-528.
33. Subramanian J, Morgensztern D, Goodgame B, et al. Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young: a surveillance, epidemiology, and end results (SEER) analysis. J Thorac Oncol 2010;5:23-28.
34. Ramalingam S, Pawlish K, Gadgeel S, et al. Lung cancer in young patients: analysis of a Surveillance, Epidemiology, and End Results database. J Clin Oncol 1998;16:651-657. (Pubitemid 28135612)
35. Owonikoko TK, Ragin CC, Belani CP, et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol 2007;25:5570-5577.
36. Zhang J, Chen SF, Zhen Y, et al. Multicenter analysis of lung cancer patients younger than 45 years in Shanghai. Cancer 2010;116:3656-3662.